Ascletis Pharma Inc. (ASCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.8777
0.00 (0.00%)
At close: Apr 24, 2025
Ascletis Pharma Employees
Ascletis Pharma had 231 employees as of December 31, 2024. The number of employees increased by 12 or 5.48% compared to the previous year.
Employees
231
Change (1Y)
12
Growth (1Y)
5.48%
Revenue / Employee
$761
Profits / Employee
-$178,481
Market Cap
778.68M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
Ascletis Pharma News
- 5 days ago - Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA - PRNewsWire
- 27 days ago - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist - PRNewsWire
- 5 weeks ago - Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025 - PRNewsWire
- 6 weeks ago - Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide - PRNewsWire
- 2 months ago - Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 - PRNewsWire
- 3 months ago - Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update - PRNewsWire
- 4 months ago - Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model - PRNewsWire
- 6 months ago - Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity - PRNewsWire